The Food and Drug Administration on Friday approved a generic version of the antiretroviral medication Videx EC (ddI) made by Woodcliff, N.J.-based Barr Laboratories for use in developing countries. Videx EC is sold in the United States by Bristol-Myers Squibb. Barr Laboratories submitted applications with the FDA to manufacture, market, and sell the generic version of the drug in 200-milligram, 250-milligram, and 400-milligram capsules. Barr plans to launch the generic drugs immediately and make them available for purchase through the President's Emergency Plan for AIDS Relief, which focuses on HIV prevention and treatment in 15 developing countries. "We applaud the FDA for expediting the review for this important medicine in the fight against AIDS, which allows us to bring a more cost-effective version of this therapy to patients who need it sooner than would have otherwise been possible," said Barr Laboratories chairman and CEO Bruce Downey.
Search
AI Powered
Human content,
AI powered search.
Latest Stories
Stay up to date with the latest in LGBTQ+ news with The Advocate’s email newsletter, in your inbox five days a week.
@ 2026 Equal Entertainment LLC.
All rights reserved
All rights reserved
By continuing to use our site, you agree to our Privacy Policy and Terms of Use.
The Latest
Support Independent Journalism
LGBTQ+ stories deserve to betold.
Your membership powers The Advocate's original reporting—stories that inform, protect, and celebrate our community.
Become a Member
FOR AS LITTLE AS $5. CANCEL ANYTIME.
More For You
Most Popular
@ 2026 Equal Entertainment LLC. All Rights reserved















